Viridian Therapeutics Inc [NASDAQ: VRDN] gained 12.61% on the last trading session, reaching $27.5 price per share at the time.
Viridian Therapeutics Inc represents 93.09 million in outstanding shares, while the company has a total market value of $2.56 billion with the latest information. VRDN stock price has been found in the range of $24.93 to $28.6.
If compared to the average trading volume of 1.06M shares, VRDN reached a trading volume of 4979616 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Viridian Therapeutics Inc [VRDN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VRDN shares is $41.13 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VRDN stock is a recommendation set at 1.12. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Jefferies have made an estimate for Viridian Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 25, 2025. While these analysts kept the previous recommendation, Wells Fargo dropped their target price from $37 to $27. The new note on the price target was released on December 19, 2024, representing the official price target for Viridian Therapeutics Inc stock. On September 11, 2024, analysts increased their price target for VRDN shares from 30 to 38.
The Price to Book ratio for the last quarter was 7.20, with the Price to Cash per share for the same quarter was set at 5.27.
Trading performance analysis for VRDN stock
Viridian Therapeutics Inc [VRDN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 16.23. With this latest performance, VRDN shares gained by 28.75% in over the last four-week period, additionally plugging by 115.18% over the last 6 months – not to mention a rise of 43.45% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VRDN stock in for the last two-week period is set at 73.64, with the RSI for the last a single of trading hit 1.56, and the three-weeks RSI is set at 1.27 for Viridian Therapeutics Inc [VRDN]. The present Moving Average for the last 50 days of trading for this stock 21.12, while it was recorded at 24.25 for the last single week of trading, and 16.93 for the last 200 days.
Viridian Therapeutics Inc [VRDN]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Viridian Therapeutics Inc [VRDN] shares currently have an operating margin of -463.52% and a Gross Margin at 98.50%. Viridian Therapeutics Inc’s Net Margin is presently recorded at -405.28%.
Viridian Therapeutics Inc (VRDN) Capital Structure & Debt Analysis
According to recent financial data for Viridian Therapeutics Inc. ( VRDN), the Return on Equity (ROE) stands at -47.40%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -42.53%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Viridian Therapeutics Inc’s Return on Invested Capital (ROIC) is -54.54%, showcasing its effectiveness in deploying capital for earnings.
Viridian Therapeutics Inc (VRDN) Efficiency & Liquidity Metrics
Based on Viridian Therapeutics Inc’s (VRDN) latest financial statements, the Debt-to-Equity Ratio is 0.05%, indicating its reliance on debt financing relative to shareholder equity.
Viridian Therapeutics Inc (VRDN) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Viridian Therapeutics Inc. (VRDN) effectively leverages its workforce, generating an average of -$2006223.78 per employee. The company’s liquidity position is robust, with a Current Ratio of 11.28% and a Quick Ratio of 11.28%, indicating strong ability to cover short-term liabilities.
Viridian Therapeutics Inc [VRDN]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Viridian Therapeutics Inc posted -0.81/share EPS, while the average EPS was predicted by analysts to be reported at -1.04/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.23. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for VRDN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Viridian Therapeutics Inc go to 23.17%.
An analysis of Institutional ownership at Viridian Therapeutics Inc [VRDN]
There are presently around $119.04%, or 119.23%% of VRDN stock, in the hands of institutional investors. The top three institutional holders of VRDN stocks are: FMR LLC with ownership of 9.57 million shares, which is approximately 14.9924%. BLACKROCK INC., holding 4.77 million shares of the stock with an approximate value of $$62.1 million in VRDN stocks shares; and BLACKROCK INC., currently with $$51.05 million in VRDN stock with ownership which is approximately 6.145%.
